ArticleBMC gastroenterology2025
EZH1 Inhibition attenuates apoptosis and promotes regeneration for liver repair in acute liver failure.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundAcute liver failure (ALF) is a life-threatening clinical syndrome characterized by massive hepatocyte death and insufficient regenerative response. However, the epigenetic mechanisms that disturb the balance between cell death and regeneration remain largely unclear. MATERIALS AND
methodsWe integrated transcriptomic data from public ALF patient cohorts, a CCl₄-induced murine ALF model, and an APAP-induced murine ALF model. Bioinformatic analyses included single-sample gene set enrichment analysis (ssGSEA) and weighted gene co-expression network analysis (WGCNA). The functional role of EZH1 was validated using EZH1 knockout mice, and liver injury was evaluated by serum biochemistry, histopathology, and immunohistochemistry.
resultsIntegrated transcriptomic analysis revealed concurrent activation of apoptotic and proliferative pathways in ALF (P < 0.001). WGCNA identified EZH1 as a key hub gene strongly correlated with both apoptosis and proliferation (cor > 0.5, P < 0.001). Patients with low EZH1 expression exhibited significantly reduced apoptotic signaling (P < 0.05) and enhanced regenerative signatures (P < 0.001). In vivo, Ezh1 knockout markedly alleviated liver injury, as indicated by reduced serum ALT and AST levels (P < 0.01), decreased levels of GSH (P < 0.05) and MDA (P < 0.01), and fewer TUNEL-positive apoptotic cells (P < 0.01), accompanied by increased Ki67- (P < 0.01) and PCNA-positive cells (P < 0.05).
conclusionsOur findings identify EZH1 as a pivotal epigenetic regulator promoting hepatocyte apoptosis in ALF. Targeted inhibition of EZH1 may offer a promising therapeutic approach to restore the balance between hepatocyte death and regeneration, thereby facilitating liver repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.